诺和诺德

最新新闻

• 评级变动
  Goldman Sachs Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Cuts Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/3/3
• 评级变动
  Morgan Stanley Upgrades Novo-Nordisk A/S(NVO.US) to Hold Rating, Cuts Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/3/3
• 评级变动
  Deutsche Bank Downgrades Novo-Nordisk A/S(NVO.US) to Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/2/23
• 评级变动
  BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/6/22
• Novo-Nordisk A/S (NVO.US) has submitted a marketing application in China for Wegovy tablets for long-term weight management.
  Zhitong Finance · 2026/8/27
• 评级变动
  Goldman Sachs Downgrades Novo-Nordisk A/S(NVO.US) to Hold Rating, Cuts Target Price to $41
  \u5e02\u573a\u8d44\u8baf · 2026/3/3
• 评级变动
  Goldman Sachs Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Raises Target Price to $47
  \u5e02\u573a\u8d44\u8baf · 2026/6/3
• 评级变动
  BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Cuts Target Price to $45
  \u5e02\u573a\u8d44\u8baf · 2026/2/25
• 评级变动
  TD Cowen Downgrades Novo-Nordisk A/S(NVO.US) to Hold Rating, Cuts Target Price to $42
  \u5e02\u573a\u8d44\u8baf · 2026/3/10
• TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $47
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Nordea Markets Initiates Novo-Nordisk A/S(NVO.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/2/24
• 评级变动
  Analysts' Opinions Are Mixed on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), AbbVie (ABBV) and Novo Nordisk (NVO)
  TipRanks · 2026/8/3
• 评级变动
  Berenberg Bank Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Cuts Target Price to $47
  \u5e02\u573a\u8d44\u8baf · 2026/3/12
• 评级变动
  Analysts' Opinions Are Mixed on These Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN) and Novo Nordisk (NVO)
  TipRanks · 2026/3/10
• Morgan Stanley Downgrades Novo-Nordisk A/S(NVO.US) to Sell Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• 评级变动
  BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Raises Target Price to $47
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO) and Hinge Health, Inc. Class A (HNGE)
  TipRanks · 2026/3/10
• 评级变动
  BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/2/24
• BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $47
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• Novo-Nordisk A/S (NVO.US) Q2 earnings beat expectations and full-year guidance was raised, yet underlying concerns persist! Weak sales of oral Wegovy cast a shadow over its path back to growth.
  Zhitong Finance · 8/5
• Eli Lilly and Co (LLY.US) and Novo-Nordisk A/S (NVO.US) win GLP-1 antitrust lawsuit as U.S. court dismisses allegations by rival pharmacy
  Zhitong Finance · 8/7
• BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $47
  \u5e02\u573a\u8d44\u8baf · 8/18

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。